Log in
FREE 15-Day Trial
Intelligent Investor
Intelligent Investor
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Shares
  5. Acrux Limited (ACR)
  6. Company Announcements

Acrux Limited (ASX: ACR) - Announcements

Current share price for ACR : $0.060 0.001 (1.64%)

ASX company news and announcements for Acrux Limited (ACR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Acrux Limited (ACR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Acrux Limited (ACR), please use our Company Announcements tool to search across all ASX-listed companies.

Intelligent Investor free trial for buy hold sell stock recommendations

Latest company announcements for Acrux Limited (ACR)

Search all Announcements
Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg		 Gain/Loss
$17 Appendix 3B 18 Feb 2019 12:43PM $0.175 $0.060 $0.060 fallen by 65.71%
$17 Appendix 3B 5 Feb 2019 4:21PM $0.180 $0.060 $0.060 fallen by 66.67%
$17 Acrux Receives $2.057m R&D Tax Incentive Rebate 21 Jan 2019 3:42PM $0.200 $0.060 $0.060 fallen by 70%
$17 End of Year Update 20 Dec 2018 8:51AM $0.180 $0.060 $0.060 fallen by 66.67%
$17 Appendix 3B 23 Nov 2018 4:52PM $0.195 $0.060 $0.060 fallen by 69.23%
$17 Change of Director's Interest Notice 13 Nov 2018 5:40PM $0.215 $0.060 $0.060 fallen by 72.09%
$17 2018 AGM Results 1 Nov 2018 12:42PM $0.220 $0.060 $0.060 fallen by 72.73%
$17 2018 AGM Script 1 Nov 2018 8:44AM $0.215 $0.060 $0.060 fallen by 72.09%
$17 2018 AGM Presentation 1 Nov 2018 8:40AM $0.215 $0.060 $0.060 fallen by 72.09%
$17 Change of Director's Interest Notice 19 Oct 2018 8:58AM $0.235 $0.060 $0.060 fallen by 74.47%
$17 Acrux has second generic dossier accepted for review by FDA 17 Oct 2018 8:58AM $0.210 $0.060 $0.060 fallen by 71.43%
$17 Acrux confirms patent challenge for generic of efinaconazole 24 Sep 2018 9:11AM $0.275 $0.060 $0.060 fallen by 78.18%
$17 Notice of 2018 Annual General Meeting/Proxy Form 21 Sep 2018 8:34AM $0.270 $0.060 $0.060 fallen by 77.78%
$17 2018 Annual Report 21 Sep 2018 8:33AM $0.270 $0.060 $0.060 fallen by 77.78%
$17 Updated Acrux Investor Presentation 18 Sep 2018 8:40AM $0.230 $0.060 $0.060 fallen by 73.91%
$17 2018 Annual Results and Investor Presentation 16 Aug 2018 4:55PM $0.215 $0.060 $0.060 fallen by 72.09%
$17 Appendix 4G 16 Aug 2018 4:23PM $0.215 $0.060 $0.060 fallen by 72.09%
$17 Appendix 4E and 2018 Financial Report 16 Aug 2018 4:21PM $0.215 $0.060 $0.060 fallen by 72.09%
$17 Investor Conference Call 2018 Annual Results 14 Aug 2018 11:36AM $0.200 $0.060 $0.060 fallen by 70%
$17 Acrux Submits First-To-File Generic of Jublia 2 Aug 2018 9:39AM $0.155 $0.060 $0.060 fallen by 61.29%
$17 Becoming a substantial holder 10 Apr 2018 4:49PM $0.175 $0.060 $0.060 fallen by 65.71%
$17 Change of Director's Interest Notice 26 Feb 2018 12:21PM $0.165 $0.060 $0.060 fallen by 63.64%
$17 Correction Half-Year Financial Report 31 December 2017 23 Feb 2018 3:52PM $0.165 $0.060 $0.060 fallen by 63.64%
$17 Investor Presntation 20 Feb 2018 4:53PM $0.160 $0.060 $0.060 fallen by 62.50%
$17 Appendix 4D and Half-Year Report to 31 December 2017 20 Feb 2018 3:57PM $0.160 $0.060 $0.060 fallen by 62.50%

251 - 275 of 546 results

Page 11 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.